EMD 521873

BIOLOGICAL2 trials

Sponsors

Merck KGaA, Darmstadt, Germany

Conditions

Lung CancerNon Small Cell Lung CancerNon-Hodgkin Lymphoma

Phase 1

EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)

CompletedNCT00879866

Merck KGaA, Darmstadt, GermanyLung Cancer, Non Small Cell Lung Cancer

Start: 2009-04-30End: 2012-09-30Updated: 2014-06-23

EMD 521873 in Advanced Solid Tumors, MTD Finding

CompletedNCT01032681

Merck KGaA, Darmstadt, GermanyNon-Hodgkin Lymphoma

Start: 2006-12-31End: 2012-01-31Updated: 2014-07-31

Related Papers

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.

2015-01-2767 citations